Skip to Content
scroll

NOVO Nordisk ADR (NVO US)

NVO US $56.34

20 MINUTE DELAYED

14 DAYS FREE ACCESS

Join Market Matters and get full access
to all our Opinion + Action

LEARN MORE

NVO US $56.34

20 MINUTE DELAYED

TODAY

0.00 %

1 YEAR RETURN

0.00%

VOLUME

340,365

DIV YIELD

0.00%

PE RATIO

14.29

52 WEEK RANGE

45.05

139.74

ANALYSIS

i

SHARE PRICE ACTIVITY
Last (Price)

56.34

Change

0.00 (0.00)

Bid / Ask

55.19 - 55.23

Volume

340,365

Turnover

9,474,544

Open

0.00

Day Range

56.25 - 58.34

VWAP

0.00

Prev Close

56.34

Last Trade

i

KEY INFORMATION
Sector

Shares Issued

NTA/Share

0.00

Last Dividend

1.73

Dividend Ex Date

18 AUG 2025

Dividend Pay Date

26 AUG 2025

i

BROKER CALLS

current

Mean

0.00

Target Price

0.00

i

CURRENT ()
Revenue

EBITDA

Profit

Earnings Per Share (EPS)

0

Dividend Per Share (DPS)

0

Yield %

3.07

Market Cap

0

Price to Earnings Ratio (P/E)

14.291

i

TARGET PRICE FORECAST

i

ESTIMATES ()
Revenue

0.00

EBITDA

0.00

Profit

0.00

Earnings Per Share (EPS)

0.00

Dividend Per Share (DPS)

0.00

i

BROKER CONSENSUS RECOMMENDATION

BUY

SELL

Target Price

0.00

Lt Growth Rate

0.00

Recommendation ()

0.00
OPINION
ACTION
image description

Business Summary

Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.

image description

Only available to Members

Take a free 14 day Market Matters trial – full access to all our reports, portfolios, positions, buy and sell recommendations. Access the latest views on the latest developments from professional money managers. It's free and no payment details are required
For membership options and pricing. Click here
Back to top